Introduction
Osteoporosis is considered one of the common features in patients with infl ammatory rheumatic diseases, contributing to a signifi cant decrease in quality of life, predominantly due to fragility fractures [1] [2] [3] . Bone is aff ected negatively by the disease process and often by the therapy itself [4] [5] [6] . Th e clinical relevance of osteoporosis in these diseases is still underestimated.
Psoriatic arthritis (PsA) is a chronic infl ammatory arthritis of unknown aetiology associated with psoriasis [7, 8] . It is classifi ed in spondyloarthropathies, a group of rheumatic diseases that share similar clinical, genetic, histological, and immunohistochemical patterns. PsA itself is characterised by synovitis, enthesitis, dactylitis and spondylitis usually accompanied with skin and very often nail psoriasis [8] . Apart from chronic infl ammation, medications such as methotrexate or steroids, and sometimes prolonged immobilization due to joint pain have been recognized as possible risk factors that contribute to bone loss in those patients [9] . In spite of that in PsA there is a lot of controversy about it, as the results of bone status in these patients are still confl icting [10] [11] [12] [13] .
Also, there is a very limited number of studies which evaluated simultaneously a disease activity and/or functional capacity on one side and bone density on the other side in patients with PsA [14] . Th erefore, the aim of this cross-sectional study was to add the evidence regarding bone mineral density (BMD) in PsA, as well as to investigate its association with some measures of disease activity and with measures of functional limitations.
Materials and methods

Subjects
Sixty-nine ambulatory, community-dwelling patients (31 men and 38 women) with established PsA, recruited from the out-patient clinic database of the University Hospital, were asked to participate in the study. Th e only additional criterion was that none have been receiving (in the past or present) specifi c medications for treatment of osteoporosis. Th e diagnosis of PsA was reconfi rmed by one rheumatologist experienced in PsA (SG). No patients previously diagnosed to have PsA were excluded due to having diff erent rheumatic condition at the time of the study. According to medical record, no patient had other disease or condition that aff ects bone metabolism (i.e. hyperparathyreoidism, hyperthyreosis, hepatic or renal failure, alcoholism or malnutrition).
Th e study was approved by the Ethics Committee of the University Hospital Center "Sisters of Mercy" in Zagreb (Croatia).
Prior to inclusion to the study, an informed consent was obtained from all participants.
Data collection
Data were collected using an interviewer-administered questionnaire. Besides demographics (age, gender), history data included duration of psoriasis and duration of symptoms and signs of arthritis, as well as previous or current treatment with disease-modifying antirheumatic drugs (DMARDs) and/or corticosteroids.
Measures of disease activity and severity
Th e morning stiff ness duration was determined (in minutes). Physical examination included the number of tender joints and number of swollen joints, as well as presence of dactylitis and number of aff ected fi ngers (hands and feet) and presence of enthesitis along with number of aff ected entheses. For the count of tender and swollen joints the American College of Rheumatology (ACR) joint count (68 tender and 66 swollen joints; hips are not assessed for swelling) was obtained [15] . Th e presence or absence of enthesitis was based on the Maastricht Ankylosing Spondylitis Enthesitis Score (MASES), ranging from 0 to 13 and representing the number of entheses painful on palpation [16] . Patient's and physician's global assessments were estimated using a 100 mm horizontal visual analogue scale (VAS).
Infl ammatory activity was measured by two standard laboratory parameters: erythrocyte sedimentation rate (ESR, Westergren's method, normal values in men <15 mm/h and in women <20 mm/h) and C-reactive protein (CRP, ELISA, normal values <5 mg/L) which were determined in fresh samples.
Disease Activity Score (DAS) 28 (range 0-10) was used as a composite indicator of disease activity. Th e score is calculated from the following variables: 28 tender joint count/swollen joint count (knees, shoulders, elbows, wrists, metacarpophalangeal and proximal interphalangeal joints of the hand), erythrocyte sedimentation rate (ESR) and global health [17, 18] . A score >5.1 indicates high disease activity, ≤5.1 and >3.2 moderate disease activity, ≤3.2 and ≥2.6 low disease activity, and <2.6 indicates remission. Cumulative steroid dose was calculated by multiplying prednisolone (or equivalent glucorticoid) daily dose with days of treatment.
Measures of functional status
Functional ability was assessed by Health Assessment Questionnaire (HAQ) for all patients. HAQ (range 0-3) is a standard self-report functional status measure. HAQ-DI (disability index) consists of 20 questions that cover 8 domains of daily living. Th e scores for all 8 domains are averaged to obtain an overall score on a 4-level response scale from 0 (no disability) to 3 (severe disability), with a notion that highest sub-category score determines the value of each category [19] . HAQ-DI was successfully used in clinical trials of PsA and hence was proposed as an useful tool for measuring functional ability in these patients [20] . ) was measured by dual-energy X-ray absorptiometry at the lumbar spine (L2-L4) and at the left hip (total hip and femoral neck) in standard manner. Callibration with a lumbar spine phantom is performed weekly. Th e patients were categorized according to WHO defi nition: osteoporosis if T score was less than -2.5 SD, osteopenia if T score was between -1.0 to -2.5 SD and normal T score if values were better than -1.0 SD [21] . Given that there is no control group, in order to provide the information on how patient population performs as compared to an age-and sexmatched controls; the results were expressed as Z scores, too.
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Statistics
Data were analyzed using the software SPSS, ver 14. Th e results were shown as mean ± standard deviation. Diff erences in means between men and women were tested using Student's t-test. Th e relationship between two variables was tested with the linear correlation. Th e normality of distribution within variables was tested using the Kolmogorov-Smirnov test. Variables which were not distributed normally (morning stiff ness, swollen joint count, CRP) were recalculated to the new variables, using the logarithmic function. Statistical signifi cance was set up at p < 0.01.
Results
Th e mean age was 54.3 ± 12.1 years for men and 57.7 ± 12.2 for women (Table 1) . Th ere were 27 (39.1%) patients on steroid therapy. Eleven patients (15.9%) have been receiving methotrexate and 19 patients (27.4%) sulphasalazine.
Duration of the disease was longer, although not significantly, in women than in men. Women were also older than men. Dactylitis was observed in 45.2% patients, mostly aff ecting up to 3 fi ngers (33.9% of the total sample), while clinical signs of enthesitis were observed in 78.1% of patients.
According to WHO classifi cation of osteoporosis, most patients had an osteoporosis at the lumbar spine (7.2%), following with the femoral neck (2.9%) (Fig. 1) . Around 80% of patients had a normal BMD at the total hip. Women had lower BMD than men at each region, but the diff erence was not statistically signifi cant.
Parameters of disease activity and functional disability were generally higher in women than in men ( Table 2) . Number of sites with clinical signs of enthesitis was significantly higher in women than in men (p = 0.009).
Th ere was no signifi cant correlation of any of measures of disease activity with BMD at any site (Table 3) . No significant diff erence in BMD at each measured region was found between patients with <5 and with >5 fi ngers/toes aff ected in a clinical form of dactylitis. Higher cumulative steroid dose was associated with lower lumbar spine BMD and Z score. Th ere was a negative correlation between HAQ scores and total hip BMD i.e. higher the HAQ score lower was total hip BMD.
Discussion
In our sample of middle-aged patients with PsA the prevalence of osteoporosis was approximately 7%. Th e comparison of prevalence of osteoporosis between our patients and other population depends on the source of data. As for Croatian population there are few data. According to the study of Cvijetić et al. the prevalence of osteoporosis in healthy people, aged 20 to 79 years is 6% in women and 4% in men [22] . Using morphometric vertebral measurement on lateral radiographs of thoracic and lumbar spine Grazio et al. found prevalence of vertebral fractures to be 11.8% (15.8% men, 9.7% women) in a population aged 50 and above [23] . Approximate prevalence of osteoporosis in United States is 10.3% [24] . In Germany 7.8 million persons (6.5 million women) were aff ected by osteoporosis, in 2003 [25] , while prevalence of osteoporosis in women 45 years and older was 14.2% [26] . Based on reported data, we may conclude that the osteoporosis in our patients with PsA is not more prevalent than in general population.
Results from other studies are diff erent. Frediani and coauthors found signifi cantly lower BMD in patients with PsA than in healthy subjects regardless of sex, menopausal status, or age [10] . Another study which included only patients with psoriasis and controls without psoriasis revealed that osteoporosis was signifi cantly more frequent in men with psoriasis compared with the controls, but not in women [27] . In a small study of patients with plaque psoriasis those with associated psoriatic arthropathy had a signifi cantly lower mean lumbar spine Z-score (-1.16) than those without arthropathy (+1.38, P = 0.015), while neither previous nor current treatment with systemic [28] . However, several other studies have determined normal total, peripherial or periarticular bone mass in patients with PsA, i.e. it was not diff erent from the control group [11] [12] [13] . In their study of comparing patients with psoriasis and patients who also had psoriatic arthritis Borman et al. did not fi nd any signifi cant diff erence in BMD [29] . In the most recent study Pedreira et al. analyzed bone density separately in postmenopausal women with psoriasis, PsA and in controls and found no signifi cant differences between those groups, too [30] .
As it is well known that chronic infl ammation is an important factor for bone loss the possible correlations were investigated in our sample of PsA patients. Infl ammatory process may infl uence bone metabolism because of proinfl ammatory mediators interleukin-1, interleukin-6, and tumour necrosis factor (TNF)-alpha), which stimulate osteoclast activity and consequently a bone loss [8, 31, 32] . As for the role of TNF-alpha it is also well known that anti-TNF alpha therapy has a benefi cial eff ect on bone density and bone turnover markers. In a review by Barnabe and Hanley who summarized the results of 3 studies in patients with spondyloarthopathies, an increase in BMD at the lumbar spine (3.2-3.6%) and at the hip (1.8-2.2%) was demonstrated as a result of TNF-alpha antagonist therapy [33] . In those studies, changes in markers of bone remodelling showed a modest increase in formation and decline in resorption. It is of note that none of the patients in our group was treated with biologic therapy. It has been indicated the existence of association between chronic infl ammation and bone loss through the action of osteoprotegerin (OPG) and receptor activator of nuclear factor-κB ligand (RANKL). Since activated T-cells produce and secrete RANKL, the RANKL/OPG system may play an important role in the pathogenesis of infl ammatory diseases, including arthritis [34] . On the other hand, OPG increases bone density by acting as a decoy receptor for RANKL. Th is inverse eff ect of OPG on osteoporosis and arthritis may probably explain a relatively preserved bone mass in our patients. In various studies, alterations of OPG serum levels have been diff erently linked to infl ammatory diseases, including not only PsA but also the other most prevalent spondyloarthropathy, ankylosing spondylitis (AS) [8] .
AS and PsA share common genetic, clinical and radiological features. PsA radiological changes include both destructive changes (e.g. erosions) and new bone formation, original article
Osteoporosis in psoriatic arthritis: Is there any? wkw 23-24/2011 © Springer-Verlag the latter being the main radiological characteristic of AS [35, 36] . In spite of bony growth in AS osteoporosis of the lumbar spine was found in up to 34.3% and osteoporosis of the hip in up to 29% patients [37] [38] [39] [40] [41] [42] . Moreover, Capaci et al. found that even 61.6% of patients with mild AS had spinal osteoporosis and osteopenia, while 46.6% had osteoporosis and osteopenia at the total hip [43] .
One must bear in mind that PsA arthritis is a heterogeneous disease. Although two main clinical patterns can be identifi ed (peripheral disease and axial disease) PsA usually presents as oligoarticular and mild disease. But, in considerable proportion of patients with time PsA becomes polyarticular and in those patients poorer physical function and health related quality of life is observed [7] . Health outcomes and especially osteoporosis in the rheumatic diseases have been a very active area of research in the past years, with a signifi cant number of published studies, although most of them have been in the area of rheumatoid arthritis (RA) or, in a lesser extent of AS [44] [45] [46] [47] [48] [49] . Although a joint damage is generally greater in RA than in PsA it has been shown that, after equivalent disease duration, function and quality of life scores are similar for both groups [50] .
Our results did not show signifi cant correlations between BMD and measures of disease activity. Moreover, duration of disease was not a signifi cant predictor of bone density. For these results we do not have a straight explanation. As according to the fi nding of moderately high DAS 28 and small elevation of ESR and CRP above normal values one can infer that high activity of the disease whose natural course is characterized by exacerbation and remission might not be long enough.
In our study negative correlations between cumulative steroid dose and lumbar spine BMD and Z score were observed. Th e role of low-dose corticosteroid treatment as an independent risk factor for osteoporosis in rheumatic diseases is still controversial. Most studies on that relationship have been focused on patients with RA [51] . Th erefore, our results contribute to the knowledge that cumulative steroid dose might be linked with osteoporosis in patients with PsA.
As for functional ability score (HAQ) we found its negative correlation with total hip BMD. It could be explained with the fact that decreased mobility associated with lower functional capacity could contribute to osteoporosis. It is of note that in our study measures of disease activity and functional ability were obtained using established methods. However, although their use in PsA has become acceptable and for some even recommended none of disease activity measurements and functional indices is specifi cally designed for PsA, as they are "borrowed" from RA and AS. It is also known that most of those scores are better suited for clinical trials [52] . In PsA, MID for HAQ-DI, pain is shown to be the best predictors for a patient's perception of overall changes in disease status [53] . It should be emphasized on the limitation of DAS28 in assessing disease activity in PsA, because it does not include distal interphalangeal joints of the hands, as well as feet. Nevertheless, DAS28 is a measure with absolute value it has been proven that it might be a valuable tool to assess disease activity in PsA patients included in clinical trials [54] . It was found that indices of disease activity performed better than the single variables and the DAS28 low-disease activity criterion performed as well as the ACR20, PsARC (Psoriatic Arthritis Response Criteria) and OMERACT criteria. Th erefore, we felt that keeping DAS28 is of more value that omitting it. Frediani et al. found that demineralization was not related to the indices of infl ammation (ESR, CRP) or disease duration, but there was a signifi cant correlation between BMD and HAQ score both in men and postmenopausal women [10] . Results from the study where BMD was measured using ultrasound showed that values were unrelated to disease duration or to ESR and C-reactive protein [55] . Also, in the sample of patients with PsA from India, no correlation was found between BMD and the duration of the disease [56] .
It seems that in patients with RA, the indicators of disease activity are better correlated to bone mass. In cross sectional and prospective studies infl ammatory disease activity may be the most important factor associated with bone loss and fractures in RA, compared with well known risk factors such as menopausal status, low BMI, reduced physical activity and corticosteroids [57] [58] [59] .
Th e main limitation of the study is the lack of control group, which may enable a direct comparison of osteoporosis prevalence and risk factors between patients and matched controls. However, due to the fact that fi nding of osteoporosis in our sample of patients was relatively low, we think that direct comparison of BMD with matching control group would not have added new information. Th e cross-sectional design is another limitation inherent in the study design. Diversity of types of PsA i.e. not having a uniform group in that respect might have somewhat infl uenced our results, too.
Th e group of patients in our study is likely to be subject to residual confounding by body mass index, calcium and vitamin D intake and other unmeasured risk factors. Th ere could be misclassifi cation with the diagnoses of PsA as we did not use any formal classifi cation criteria, although it is not likely, because the diagnosis was established by experienced rheumatologist.
Conclusions
Patients in our sample with long-term PsA had low prevalence of osteoporosis. Indicators of disease activity did not correlate signifi cantly with measures of bone mass. Higher HAQ scores correlated with lower total hip BMD while higher cumulative steroid dose was associated with lower lumbar spine BMD and Z score.
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